Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cystic Fibrosis Buyers’ Club

- PMLiVE

Vertex scores FDA approval for CF triple therapy Trikafta

Decision comes only a few months after therapy was filed

- PMLiVE

Labour Party takes aim at pharma, calls attention to Orkambi row

Proposal to introduce compulsory licensing faces industry criticism

- PMLiVE

Vertex eyes type 1 diabetes cure with biotech acquisition

Will acquire Semma Therapeutics for $950m

- PMLiVE

Vertex faces rejection of its CF medicines in Scotland

Another rejection over cost-effectiveness

- PMLiVE

Leiden reassures on key role at Vertex

Reshma Kewalramani to be new CEO, but Leiden will retain portfolio

- PMLiVE

Who’s calling the shots in European healthcare?

Patients versus Pharma: industry too powerful, and too cosy with EMA, says Yannis Natsis

- PMLiVE

The fight for affordable insulin

Activists are organised, and demanding action on US insulin prices - and pointing the finger at pharma

- PMLiVE

The Cystic Fibrosis Buyers’ Club

Patients versus Pharma: campaigners using direct action to fight for access

- PMLiVE

Vertex files cystic fibrosis triple therapy with FDA

A landmark for company - but pricing controversy awaits

- PMLiVE

Orkambi row: government now considering Crown Use licensing

MPs call for radical solutions as deadlock remains

- PMLiVE

Buyers’ Club wants government support on Orkambi imports

Proposes three point plan to work round impasse

- PMLiVE

Vertex eyes Duchenne market with Exonics, CRISPR deals

Biotech has gene-editing expertise

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links